CG Oncology (CGON) Revenue (2023 - 2026)

CG Oncology posted quarterly Revenue of $1.1 million for Q1 2026, up 1982.69% year-on-year from $52000.0 in Q1 2025, and down 53.36% on a QoQ basis from $2.3 million in Q4 2025.

CG Oncology (CGON) has 4 years of Revenue data on file, last reported at $1.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Revenue rose 1982.69% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 666.01% YoY), and the FY2025 full-year result was $4.0 million, up 254.7% from the prior year.
  • Revenue for Q1 2026 stood at $1.1 million, down from $2.3 million in the prior quarter.
  • Across five years, Revenue topped out at $2.3 million in Q4 2025 and bottomed at $1000.0 in Q4 2023.
  • The 4-year median for Revenue is $194000.0 (2023), against an average of $587818.2.
  • The widest annual swing landed in 2024, when Revenue jumped 45500.0%; it then plunged 90.17% in 2025.
  • A 4-year view of Revenue shows it stood at $1000.0 in 2023, then surged by 45500.0% to $456000.0 in 2024, then surged by 409.21% to $2.3 million in 2025, then plunged by 53.36% to $1.1 million in 2026.
  • The last three Revenue figures came in at $1.1 million (Q1 2026), $2.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.17 Bn
10 CG Oncology 5.01 Bn 5.01 Bn -1.88 Mn 1.08 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.08 Mn
Dec 31, 2025 2.32 Mn
Sep 30, 2025 1.67 Mn
Mar 31, 2025 52,000.00
Dec 31, 2024 456,000.00
Sep 30, 2024 43,000.00
Jun 30, 2024 111,000.00
Mar 31, 2024 529,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 9,000.00
Mar 31, 2023 194,000.00